Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H22N2O |
| Molecular Weight | 342.4336 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCN1N=C(C(=O)C2=CC=CC3=C2C=CC=C3)C4=C1C=CC=C4
InChI
InChIKey=VAKGBPSFDNTMDJ-UHFFFAOYSA-N
InChI=1S/C23H22N2O/c1-2-3-8-16-25-21-15-7-6-13-20(21)22(24-25)23(26)19-14-9-11-17-10-4-5-12-18(17)19/h4-7,9-15H,2-3,8,16H2,1H3
| Molecular Formula | C23H22N2O |
| Molecular Weight | 342.4336 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. | 2016 |
|
| High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. | 2016 Jan |
|
| New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites. | 2019 |
|
| Phase I metabolic profiling of the synthetic cannabinoids THJ-018 and THJ-2201 in human urine in comparison to human liver microsome and cytochrome P450 isoenzyme incubation. | 2019 Jul |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:51:08 UTC 2023
by
admin
on
Sat Dec 16 11:51:08 UTC 2023
|
| Record UNII |
B39WNG6743
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-THJ-018
Created by
admin on Sat Dec 16 11:51:08 UTC 2023 , Edited by admin on Sat Dec 16 11:51:08 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
THJ-018
Created by
admin on Sat Dec 16 11:51:08 UTC 2023 , Edited by admin on Sat Dec 16 11:51:08 UTC 2023
|
PRIMARY | THJ-018 is a synthetic cannabinoid that is the indazole analogue of JWH-018 and has been sold online as a designer drug. THJ-018 is an Anlage II controlled drug in Germany. It is also banned in Sweden. | ||
|
DTXSID90101003
Created by
admin on Sat Dec 16 11:51:08 UTC 2023 , Edited by admin on Sat Dec 16 11:51:08 UTC 2023
|
PRIMARY | |||
|
B39WNG6743
Created by
admin on Sat Dec 16 11:51:08 UTC 2023 , Edited by admin on Sat Dec 16 11:51:08 UTC 2023
|
PRIMARY | |||
|
1364933-55-0
Created by
admin on Sat Dec 16 11:51:08 UTC 2023 , Edited by admin on Sat Dec 16 11:51:08 UTC 2023
|
PRIMARY | |||
|
THJ-018
Created by
admin on Sat Dec 16 11:51:08 UTC 2023 , Edited by admin on Sat Dec 16 11:51:08 UTC 2023
|
PRIMARY | Although this substance has not been formally studied, from analysis of the structure, it is presumed that THJ-018 has a similar binding profile to that of JWH-018 and matches many of the in vivo properties of .DELTA.9-THC. As with JWH-018, THJ-018 exhibits its range of effects via full agonism of both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2. THJ-018 is around 5x the potency of .DELTA.9-THC. However, the role of these interactions and how they result in the cannabinoid high experience continues to remain elusive. | ||
|
124518671
Created by
admin on Sat Dec 16 11:51:08 UTC 2023 , Edited by admin on Sat Dec 16 11:51:08 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
||
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
